Torrent Pharmaceuticals Limited
TORNTPHARM
Rank in Stocks
#1198
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Share Price
$50.31
Last synced: 2026-10-19
Market Cap
$19.14B
Change (1 day)
-0.14%
Change (1 year)
23.83%
Country
IN
Trade Torrent Pharmaceuticals Limited (TORNTPHARM)
Category
Healthcare
P/E ratio for Torrent Pharmaceuticals Limited (TORNTPHARM)
P/E ratio as of October 2026 TTM: 71.64
According to Torrent Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 71.64. At the end of 2024 the company had a P/E ratio of 54.66.
P/E ratio history for Torrent Pharmaceuticals Limited from 2005 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 71.64 | 27.07% |
| 2025 | 56.38 | 3.14% |
| 2024 | 54.66 | 30.84% |
| 2023 | 41.78 | -31.28% |
| 2022 | 60.79 | 76.71% |
| 2021 | 34.40 | 5.65% |
| 2020 | 32.56 | -55.81% |
| 2019 | 73.70 | 133.20% |
| 2018 | 31.60 | 12.29% |
| 2017 | 28.14 | 113.73% |
| 2016 | 13.17 | -49.56% |
| 2015 | 26.11 | 95.38% |
| 2014 | 13.36 | 0.29% |
| 2013 | 13.32 | -29.07% |
| 2012 | 18.78 | 3.34% |
| 2011 | 18.18 | -8.93% |
| 2010 | 19.96 | 224.61% |
| 2009 | 6.15 | -30.48% |
| 2008 | 8.85 | -50.07% |
| 2007 | 17.72 | -50.96% |
| 2006 | 36.12 | 88.10% |
| 2005 | 19.21 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -51.20% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.